<DOC>
	<DOC>NCT01909804</DOC>
	<brief_summary>The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic genotype (GT) 1 or 3 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Body mass index (BMI) ≥ 18 kg/m^2 HCV RNA ≥ 10000 IU/mL at screening Prior treatment failure to a regimen including interferon with or without RBV HCV genotype 1 or 3 Chronic HCV infection Cirrhosis determination Use of highly effective contraception methods if female of childbearing potential or sexually active male Current or prior history of clinically significant illness other than HCV Screening ECG with clinically significant abnormalities Prior exposure to HCV specific direct acting antiviral agent Pregnant or nursing female or male with pregnant female partner Chronic liver disease of nonHCV etiology Hepatitis B Active drug abuse Use of any prohibited concomitant medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Genotype 3</keyword>
	<keyword>Treatment experienced</keyword>
</DOC>